Binnari Kim
Overview
Explore the profile of Binnari Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
196
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee S, Kim B
J Pathol Transl Med
. 2025 Jan;
59(1):84-90.
PMID: 39815746
BCOR-rearranged sarcoma was classified by the World Health Organization in 2020 as a new subgroup of undifferentiated small round-cell sarcoma. It is known to occur very rarely in the kidney....
2.
Kim B, Kim K
Cancers (Basel)
. 2023 Jan;
15(2).
PMID: 36672418
Exosomes are a subtype of extracellular vesicles ranging from 30 to 150 nm and comprising many cellular components, including DNA, RNA, proteins, and metabolites, encapsulated in a lipid bilayer. Exosomes...
3.
Kim J, Kim H, Kim B, Chung H, Chung H, Kim K, et al.
Cancer Med
. 2023 Jan;
12(7):7748-7761.
PMID: 36650632
Pancreaticobiliary tract cancer has a poor prognosis with unmet needs in a new target treatment. Some studies have reported that an enhancement of T-cell immunity is associated with a good...
4.
Kim J, Kim B, Kim E, Jang M, Cho J, Lee H, et al.
Mol Diagn Ther
. 2022 Sep;
26(6):679-688.
PMID: 36125657
Background: The PD-L1 IHC 22C3 pharmDx used on the Dako Autostainer Link 48 (ASL48) staining platform is an established method for assessing programmed death-ligand 1 (PD-L1) expression in tumor tissue...
5.
Jeon C, Kim B, Choi J
J Neurosurg Pediatr
. 2022 Feb;
29(5):513-519.
PMID: 35180693
Objective: Astroblastoma (AB) is a rare glial tumor. The optimal treatment and prognosis of this tumor remain unclear. The authors retrospectively analyzed the clinical characteristics, neuroimaging findings, histopathological results, and...
6.
Deep learning-based virtual cytokeratin staining of gastric carcinomas to measure tumor-stroma ratio
Hong Y, Heo Y, Kim B, Lee D, Ahn S, Ha S, et al.
Sci Rep
. 2021 Sep;
11(1):19255.
PMID: 34584193
The tumor-stroma ratio (TSR) determined by pathologists is subject to intra- and inter-observer variability. We aimed to develop a computational quantification method of TSR using deep learning-based virtual cytokeratin staining...
7.
Jeong S, Cho Y, Ryu J, Choi J, Hwang J, Kim B, et al.
Gynecol Oncol
. 2021 May;
162(1):173-181.
PMID: 33972086
Background: The patient-derived xenograft (PDX) model is a promising translational platform for duplicating the characteristics of primary tumors. Here, we established and characterized PDX models of uterine cancer to demonstrate...
8.
Heo Y, Kim B, Kim H, Kim S, Jang M, Kim K
Pathol Res Pract
. 2021 Jan;
218:153338.
PMID: 33440275
Programmed death-ligand 1 (PD-L1) expression in biopsies of gastric carcinoma may predict the results in corresponding surgical specimens. We compared PD-L1 immunohistochemistry (IHC) 22C3 pharmDx expression in paired biopsy and...
9.
Kim B, Kang S, Kim K
J Pathol Transl Med
. 2020 Nov;
55(1):26-32.
PMID: 33153244
The use of biomarkers to guide patient and therapy selection has gained much attention to increase the scope and complexity of targeted therapy options and immunotherapy. Clinical trials provide a...
10.
Lee J, Kim B, Jung H, La Choi Y, Sun J
Cancer Immunol Immunother
. 2020 Oct;
70(5):1203-1211.
PMID: 33123755
Introduction: Nivolumab, a programmed death 1 (PD-1) inhibitor, has recently demonstrated efficacy as second-line therapy for esophageal squamous cell carcinoma (ESCC) patients in a phase III trial. We report real-world...